Portfolio: Blueprint Neurotherapeutics Network (BPN) Program and HEAL Optimization of Non-addictive Therapies [Small Molecules and Biologics] to Treat Pain
Shared Interests: Translational research and development across all clusters and programs, Medicinal Chemistry and small molecule drug discovery and development
Dr. Charles L. Cywin joined the National Institute of Neurological Disorders and Stroke (NINDS) in 2011 in the Division of Translational Research and currently serves as the Director, Small Molecule Neurotherapeutics and has responsibility for oversight for the Blueprint Neurotherapeutics Network (BPN) and the HEAL Pain Therapeutics Development Program (PTDP). He provides project leadership and coordination for a portfolio of neuroscience drug discovery projects ranging from early discovery to Phase I trials as well as managing a suite of contracts to provide CRO and subject matter expertise to the drug discovery teams in these programs. Prior to joining NIH he spent 17 years at Boehringer Ingelheim Pharmaceuticals where he was Director, Medicinal Chemistry and was responsible for Hit to Lead and Lead Optimization programs focused on clinical candidate selection in a number of therapeutic areas. He created the lead discovery team, the parallel synthesis group and led the efforts to identify and implement new technologies, infrastructure and outsourcing in medicinal chemistry.
Dr. Cywin received his Bachelor's degree in chemistry from Providence College, performed his doctoral training at Syracuse University focused on natural product synthesis where he was a University Fellow, and completed his postdoctoral fellowship with Professor E.J. Corey at Harvard focusing on asymmetric catalysis.